KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial. PMID 36410812 · BMJ Open · 2022-Nov-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effectiveness of Intensive Versus Minimalist Follow-Up Regimen on Survival in Patients With Endometrial Cancer (TOTEM Study): A Randomized, Pragmatic, Parallel Group, Multicenter Trial. PMID 35858170 · J Clin Oncol · 2022-Nov-20 The record reports a randomized trial of follow-up intensity (intensive vs. minimalist) for endometrial cancer patients, not a drug-containing intervention. The intervention is not a drug, making it ineligible for the cohort. Phase evidence is not explicitly stated in the metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis. PMID 35802849 · J Clin Oncol · 2022-Nov-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Hemorrhagic, hypovolemic shock resuscitated with Ringer's solution using bicarbonate versus lactate: A CONSORT-randomized controlled study comparing patient outcomes and blood inflammatory factors. PMID 36401445 · Medicine (Baltimore) · 2022-Nov-18 The study is a randomized controlled trial in human trauma patients, not oncology. It compares two types of Ringer's solution for fluid resuscitation, with primary outcomes focused on complications, length of stay, and inflammatory biomarkers. There is no drug intervention (solutions are fluids/devices), no time-to-event efficacy endpoint (e.g., OS, PFS, DFS), and it is not a cancer trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of comprehensive geriatric assessment for frail elderly patients operated for colorectal cancer-the colorectal cancer frailty study: study protocol for a randomized, controlled, multicentre trial. PMID 36397083 · Trials · 2022-Nov-17 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
CT radiomics-based long-term survival prediction for locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy using features from tumor and tumor organismal environment. PMID 36384755 · Radiat Oncol · 2022-Nov-16 The study is an oncology, human, randomized, time-to-event report, but it is not a drug intervention trial. It is a secondary/prognostic biomarker study (radiomics model) using a retrospective dataset where all patients received standard concurrent chemoradiotherapy. Therefore, it does not meet the core eligibility criterion of a drug-containing intervention in a randomized Phase III/IIIb or Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
FUTURE-GB: functional and ultrasound-guided resection of glioblastoma - a two-stage randomised control trial. PMID 36379652 · BMJ Open · 2022-Nov-15 The record is a protocol for a randomized surgical trial in glioblastoma, not a completed Phase III drug trial reporting efficacy results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial. PMID 36283897 · Vaccine · 2022-Nov-15 The trial is a Phase III randomized oncology-related vaccine study with a drug intervention and original results, but it lacks the required primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The endpoints are immunogenicity (antibody titers, seroconversion rates) and safety, not time-to-event.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer. PMID 36031465 · Int J Radiat Oncol Biol Phys · 2022-Nov-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial. PMID 35678328 · Int J Cancer · 2022-Nov-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial. PMID 35667528 · Int J Radiat Oncol Biol Phys · 2022-Nov-15 The record describes a single-arm phase 2 trial of a non-drug intervention (SABR). It fails the required criteria for a drug-containing randomized phase 3 trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes. PMID 35643253 · Int J Radiat Oncol Biol Phys · 2022-Nov-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial. PMID 36376888 · BMC Cancer · 2022-Nov-14 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. PMID 35797219 · Clin Cancer Res · 2022-Nov-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
No Effect of Vitamin C Administration on Neutrophil Recovery in Autologous Stem Cell Transplantation for Myeloma or Lymphoma: A Blinded, Randomized Placebo-Controlled Trial. PMID 36432471 · Nutrients · 2022-Nov-11 The trial is randomized and oncology-related but is excluded because the intervention is a nutritional supplement (vitamin C), not a drug, and the trial phase is not confirmed as Phase III/IIIb or II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Short-term prognosis for hepatocellular carcinoma patients with lung metastasis: A retrospective cohort study based on the SEER database. PMID 36397445 · Medicine (Baltimore) · 2022-Nov-11 This is a retrospective cohort study developing a prediction model for short-term mortality in HCC patients with lung metastasis using SEER database data. Although labeled as a 'Randomized Controlled Trial' in publication types, this refers only to the random division of data into training and validation sets, not a randomized clinical trial. It lacks Phase III/IIIb or Phase II/III trial design, a drug-containing intervention arm compared to control, and a primary time-to-event efficacy endpoint. The study is a prognostic modeling exercise, not a trial report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Women's Health Initiative cancer survivorship clinic incorporating electronic patient-reported outcomes: a study protocol for the Linking You to Support and Advice (LYSA) randomized controlled trial. PMID 36357934 · Pilot Feasibility Stud · 2022-Nov-10 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Study protocol of the BASINEL Study: a pragmatic randomised controlled trial investigating treatment versus no treatment of low-risk basal cell carcinomas in older persons. PMID 36356999 · BMJ Open · 2022-Nov-10 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study. PMID 35834762 · J Clin Oncol · 2022-Nov-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Metastatic Rhabdomyosarcoma: Results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study. PMID 35709412 · J Clin Oncol · 2022-Nov-10 The record is for an oncology, human, randomized trial with drug intervention and primary time-to-event endpoints. However, the metadata does not explicitly confirm the trial phase as Phase III/IIIb or Phase II/III, which is a required criterion. Therefore, eligibility cannot be determined.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial. PMID 36351725 · BMJ Open · 2022-Nov-08 The study is a randomized Phase III oncology trial in humans with primary results, but it does not involve a drug-containing intervention (it compares diagnostic modalities) and does not report a time-to-event efficacy endpoint (e.g., OS, PFS) or Kaplan-Meier/HR analysis.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT). PMID 36351720 · BMJ Open · 2022-Nov-08 Record describes a feasibility study protocol for a future phase III trial. It is not an original report of results. It does not contain a drug intervention (only radiation techniques) and does not report a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Functional imaging-guided carbon ion irradiation with simultaneous integrated boost for localized prostate cancer: study protocol for a phase II randomized controlled clinical trial. PMID 36348363 · Trials · 2022-Nov-08 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
[Cost-effectiveness of endoscopic nasopharyngectomy in locally recurrent rT1-rT3 nasopharyngeal carcinoma: a study based on Markov model]. PMID 36404655 · Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi · 2022-Nov-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Nomogram for prediction of severe community-acquired pneumonia development in diabetic patients: a multicenter study. PMID 36344933 · BMC Pulm Med · 2022-Nov-07 The study is a retrospective cohort developing a predictive nomogram for severe community-acquired pneumonia in diabetic patients. It is not oncology-focused (though 'malignant tumor' is a covariate), does not test a drug intervention, and does not report a time-to-event efficacy endpoint. It is a primary analysis but fails multiple core eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A multimodal prehabilitation program for the reduction of post-operative complications after surgery in advanced ovarian cancer under an ERAS pathway: a randomized multicenter trial (SOPHIE). PMID 35793862 · Int J Gynecol Cancer · 2022-Nov-07 The record is a protocol for an ongoing randomized trial of a non-drug prehabilitation program in ovarian cancer, with a primary endpoint of post-operative complications, not a time-to-event efficacy outcome. It does not meet the criteria for a drug intervention, Phase III/IIIb or Phase II/III trial with results, or a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[18F]fluciclovine vs. [18F]fluorocholine Positron Emission Tomography/Computed Tomography: A Head-to-Head Comparison for Early Detection of Biochemical Recurrence in Prostate Cancer Patients. PMID 36412685 · Tomography · 2022-Nov-05 The record is a randomized controlled trial in oncology (prostate cancer) with human subjects and an original primary result. However, it is excluded because it does not meet the required criteria: (1) It is not a Phase III/IIIb or Phase II/III trial; the phase is not specified. (2) The intervention compares two diagnostic imaging radiopharmaceuticals, not a therapeutic drug. (3) The primary endpoint is detection rate (diagnostic performance), not a time-to-event efficacy endpoint like OS, PFS, or DFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol. PMID 36333773 · Reprod Health · 2022-Nov-04 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Telehealth exercise to Improve Physical function and frailty in patients with multiple myeloma treated with autologous hematopoietic Stem cell transplantation (TIPS): protocol of a randomized controlled trial. PMID 36329525 · Trials · 2022-Nov-03 This is a protocol for a randomized controlled trial assessing telehealth exercise in multiple myeloma patients post-autologous HSCT. It is an oncology topic with human subjects and randomization. However, it is ineligible because it is a protocol without results, contains no drug intervention (exercise only), lacks a primary or key secondary time-to-event efficacy endpoint (primary endpoint is physical function via SPPB), and does not report results from a Phase III/IIIb or Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of long-course neoadjuvant radiation on postoperative low anterior resection syndrome and stoma status in rectal cancer: long-term functional follow-up of a randomized clinical trial. PMID 36321379 · BJS Open · 2022-Nov-02 The record describes a secondary analysis of functional outcomes from a randomized trial in rectal cancer. While the trial is oncology, human, randomized, involves a drug intervention, and the original trial had a time-to-event primary endpoint (DFS), this specific report is not the primary efficacy result report. It does not present the Kaplan-Meier data or hazard ratio for DFS, which is the key time-to-event efficacy endpoint required. The trial phase is also not explicitly confirmed as Phase III in the provided metadata. Therefore, it does not meet the inclusion criteria for a primary formal-result report of a Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Predictive Polygenic Score for Outcome after First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients Using Supervised Principal Component Analysis. PMID 35984985 · Cancer Epidemiol Biomarkers Prev · 2022-Nov-02 This record is a secondary analysis (genetic/omic biomarker study) of two primary Phase III trials (NCTG N0147 and N9741). It does not present original primary or secondary efficacy results from a single trial but rather constructs and tests polygenic hazard scores using data from those trials. The report is not a formal-result publication of a single randomized trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial. PMID 35099555 · Inflamm Bowel Dis · 2022-Nov-02 The study is a retrospective long-term follow-up of a Crohn's disease trial, not an oncology trial. It focuses on a non-drug (mesenchymal stem cell) intervention and does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS) for malignant neoplasms.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Patient Characteristics on Uptake of Screening Using a Mailed Human Papillomavirus Self-sampling Kit: A Secondary Analysis of a Randomized Clinical Trial. PMID 36449291 · JAMA Netw Open · 2022-Nov-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The diagnostic and prognostic value of radiomics and deep learning technologies for patients with solid pulmonary nodules in chest CT images. PMID 36319968 · BMC Cancer · 2022-Nov-01 The study is a retrospective diagnostic/prognostic modeling study, not a Phase III/IIIb or Phase II/III randomized drug trial. It lacks a drug-containing intervention, which is a required criterion for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M). PMID 36308441 · JNCI Cancer Spectr · 2022-Nov-01 The study is an oncology Phase 3 randomized trial with a drug intervention and reports original primary results. However, the primary endpoint is the incidence of moderate-to-severe CIPN at month 9, which is a binary categorical endpoint, not a time-to-event (Kaplan-Meier or HR-based) endpoint. No other key secondary time-to-event efficacy endpoint is indicated in the record.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. PMID 36069821 · JAMA Surg · 2022-Nov-01 The study is a retrospective analysis of an ongoing adaptive platform trial (I-SPY2) focusing on the association of residual DCIS with survival endpoints. While the parent trial is randomized and involves drug interventions, this specific report is a secondary analysis examining a subgroup/comparison within the trial, not a primary or definitive Phase III/IIIb or Phase II/III trial result report. The phase of the parent trial is not explicitly stated as Phase III in the provided metadata, and this analysis does not meet the criteria for a definitive randomized trial report with a primary/key secondary time-to-event efficacy endpoint for the drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cost effectiveness of population screening vs. no screening for cardiovascular disease: the Danish Cardiovascular Screening trial (DANCAVAS). PMID 36029019 · Eur Heart J · 2022-Nov-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
CROSS Versus FLOT Regimens in Esophageal and Esophagogastric Junction Adenocarcinoma: A Propensity-Matched Comparison. PMID 35876385 · Ann Surg · 2022-Nov-01 The study is not a randomized trial (it is a propensity-matched comparison) and does not report a Phase III/IIIb or Phase II/III randomized trial. While it meets other criteria (oncology, human, drug intervention, time-to-event endpoint, original result), the core requirement for a randomized trial with definitive phase evidence is not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma. PMID 35850363 · Int J Radiat Oncol Biol Phys · 2022-Nov-01 The record reports a Phase 2/3 randomized trial of NBTXR3 plus RT vs RT alone in soft tissue sarcoma, but the presented results focus on safety, pathological response (pCR), and health-related quality of life. The abstract does not mention or present any time-to-event efficacy endpoint (such as OS, PFS, DFS, etc.), Kaplan-Meier analyses, or hazard ratios. Therefore, it does not meet the required criterion of having a primary or key secondary time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Two-Year Tumor Outcomes of a Phase 2B, Randomized, Double-Blind Trial of Avasopasem Manganese (GC4419) Versus Placebo to Reduce Severe Oral Mucositis Owing to Concurrent Radiation Therapy and Cisplatin for Head and Neck Cancer. PMID 35724774 · Int J Radiat Oncol Biol Phys · 2022-Nov-01 The record describes a Phase 2B trial, not the required Phase III/IIIb or Phase II/III. All other criteria (oncology, human, randomized, drug intervention, time-to-event endpoints, original results) are met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Food to Overcome Outcomes Disparities: A Randomized Controlled Trial of Food Insecurity Interventions to Improve Cancer Outcomes. PMID 35709430 · J Clin Oncol · 2022-Nov-01 The record describes a randomized trial in oncology patients, but it fails two key eligibility criteria: it does not involve a drug-containing intervention (interventions are food assistance), and it does not have a primary time-to-event efficacy endpoint (primary outcome is treatment completion).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of a bivalent, adjuvant system 04-adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15-25: a randomized, double-blind, phase III, noninferiority clinical trial. PMID 35352698 · Eur J Cancer Prev · 2022-Nov-01 The record is a Phase III randomized trial of a drug (vaccine) in oncology (HPV-related cancer prevention), but the reported outcomes are immunogenicity and safety metrics, not a formal time-to-event efficacy endpoint as required for the cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intracorporeal Versus Extracorporeal Anastomosis in Robotic Right Colectomy: A Multicenter, Triple-blind, Randomized Clinical Trial. PMID 35129520 · Ann Surg · 2022-Nov-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial. PMID 35091522 · J Pediatr Hematol Oncol · 2022-Nov-01 The study is a randomized Phase III trial of olanzapine for chemotherapy-induced nausea/vomiting in oncology patients, but its primary endpoints are rates of vomiting control and rescue medication use, not a time-to-event efficacy outcome.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A cross-sectional analysis of registered clinical trials on the use of particle beam radiation therapy in head and neck cancers. PMID 36544687 · Ann Transl Med · 2022-Nov The record is a cross-sectional analysis of registered clinical trials, not an original formal-result report of a single randomized trial with a drug intervention and time-to-event efficacy endpoint. It lacks explicit reporting of time-to-event outcomes and drug intervention.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Zhengyuan capsules for the treatment of chemotherapy-induced cancer-related fatigue in stage IIIB-IV unresectable NSCLC: study protocol for a randomized, multi-center, double-blind, placebo-controlled clinical trial. PMID 36524089 · J Thorac Dis · 2022-Nov 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Safety and effectiveness of neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection in patients with stage I-IIIA small-cell lung cancer: a retrospective single-arm clinical trial. PMID 36524062 · J Thorac Dis · 2022-Nov The study is a retrospective single-arm trial, not randomized. It does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The main outcomes are response rates (ORR, pCR, MPR) and safety, not Kaplan-Meier survival analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial. PMID 36467842 · EJHaem · 2022-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
De-escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open-label, prospective trial in China. PMID 36467815 · EJHaem · 2022-Nov The study meets criteria for oncology, human, randomized, time-to-event endpoint, drug intervention, and original results. However, it is excluded because the trial phase (Phase III/IIIb or Phase II/III) is not explicitly established in the provided metadata, which is a required criterion for eligibility. Additionally, the intervention structure (de-escalation vs. discontinuation of an existing drug) may not align with the typical 'drug-containing intervention' scope for new drug comparisons.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nomogram for predicting cancer-specific survival of patients with clear-cell renal cell carcinoma: a SEER-based population study. PMID 36454119 · Gen Physiol Biophys · 2022-Nov This is a population-based retrospective study developing a predictive nomogram using SEER database data. It is not a randomized controlled trial testing a drug intervention in a Phase III setting. Although it involves a time-to-event outcome (cancer-specific survival), it lacks all other key eligibility criteria: randomized treatment comparison, drug intervention, and trial phase. The publication type 'Randomized Controlled Trial' in metadata is misleading for this study design.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -